A novel treatment option in rheumatoid arthritis: Abatacept, a selective modulator of T-cell co-stimulation;Neue Option in der Behandlung der rheumatoiden Arthritis: Abatacept, ein selektiver Modulator der T-Zell-Kostimulation

Wiener Medizinische Wochenschrift

Volumn 159, Issue 3-4, 2009, Pages 70-75

  Dejaco, Christian ^a   Duftner, Christina ^a   Wipfler, Edith ^a   Schirmer, Michael ^a  

^a ELISABETHINEN HOSPITAL   (Austria)

Author keywords

Abatacept; Biologics; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

BIOLOGICAL THERAPY; CELL ACTIVATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SELECTIVITY; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; MONOTHERAPY; MUSCLE HYPERTONIA; NONHUMAN; PLACEBO EFFECT; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE; TREATMENT FAILURE;

EID: 61449121033     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-008-0590-3     Document Type: Review

References (39)

1. JS Smolen D Aletaha M Koeller MH Weisman P Emery 2007 New therapies for treatment of rheumatoid arthritis Lancet 370 1861 1874
2. RM Pope H Perlman 1999
3. EM Ruderman RM Pope 2006 Drug Insight: abatacept for the treatment of rheumatoid arthritis Nat Clin Pract Rheumatol 2 654 660
4. B Salomon JA Bluestone 2001 Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation Annu Rev Immunol 19 225 252
5. FA Harding JG McArthur JA Gross DH Raulet JP Allison 1992 CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones Nature 356 607 609
6. PS Linsley W Brady M Urnes LS Grosmaire NK Damle JA Ledbetter 1991 CTLA-4 is a second receptor for the B cell activation antigen B7 J Exp Med 174 561 569
7. TL Walunas CY Bakker JA Bluestone 1996 CTLA-4 ligation blocks CD28-dependent T cell activation J Exp Med 183 2541 2550
8. NJ Karandikar CL Vanderlugt TL Walunas SD Miller JA Bluestone 1996 CTLA-4: a negative regulator of autoimmune disease J Exp Med 184 783 788
9. EA Tivol F Borriello AN Schweitzer WP Lynch JA Bluestone AH Sharpe 1995 Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 Immunity 3 541 547
10. JA Bluestone EW St Clair LA Turka 2006 CTLA4Ig: bridging the basic immunology with clinical application Immunity 24 233 238
11. B Salomon DJ Lenschow L Rhee N Ashourian B Singh A Sharpe JA Bluestone 2000 B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes Immunity 12 431 440
12. C Dejaco C Duftner B Grubeck-Loebenstein M Schirmer 2006 Imbalance of regulatory T cells in human autoimmune diseases Immunology 117 289 300
13. AN Vallejo 2005 CD28 extinction in human T cells: altered functions and the program of T-cell senescence Immunol Rev 205 158 169
14. M Schirmer AN Vallejo CM Weyand JJ Goronzy 1998 Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4 + CD28 - T cells from rheumatoid arthritis patients J Immunol 161 1018 1025
15. D Schmidt JJ Goronzy CM Weyand 1996 CD4+ CD7 - CD28 - T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity J Clin Invest 97 2027 2037
16. T Namekawa MR Snyder JH Yen BE Goehring PJ Leibson CM Weyand JJ Goronzy 2000 Killer cell activating receptors function as costimulatory molecules on CD4 + CD28null T cells clonally expanded in rheumatoid arthritis J Immunol 165 1138 1145
17. LW Moreland R Alten F Van den Bosch T Appelboom M Leon P Emery S Cohen M Luggen W Shergy I Nuamah JC Becker 2002 Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dosefinding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion Arthritis Rheum 46 1470 1479
18. JM Kremer R Westhovens M Leon E Di Giorgio R Alten S Steinfeld A Russell M Dougados P Emery IF Nuamah GR Williams JC Becker DT Hagerty LW Moreland 2003 Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig N Engl J Med 349 1907 1915
19. JM Kremer M Dougados P Emery P Durez J Sibilia W Shergy S Steinfeld E Tindall JC Becker T Li IF Nuamah R Aranda LW Moreland 2005 Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, doubleblind, randomized, placebo-controlled trial Arthritis Rheum 52 2263 2271
20. M Weinblatt M Schiff A Goldman J Kremer M Luggen T Li D Chen JC Becker 2007 Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial Ann Rheum Dis 66 228 234
21. JM Kremer HK Genant LW Moreland AS Russell P Emery C Abud-Mendoza J Szechinski T Li Z Ge JC Becker R Westhovens 2006 Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial Ann Intern Med 144 865 876
22. MC Genovese JC Becker M Schiff M Luggen Y Sherrer J Kremer C Birbara J Box K Natarajan I Nuamah T Li R Aranda DT Hagerty M Dougados 2005 Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 353 1114 1123
23. M Weinblatt B Combe A Covucci R Aranda JC Becker E Keystone 2006 Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study Arthritis Rheum 54 2807 2816
24. R Westhovens J Kremer L Moreland P Emery A Russell T Li R Aranda JC Becker C Joshi M Dougados 2007 Maintained efficacy and safety of Abatacept in rheumatoid arthritis patients receiving background methotrexate through 5 years of treatment Arthritis Rheum 56 Suppl S S395 abstract
25. J Kremer R Westhovens M Luggen A Russell R Aranda JC Becker C Joshi M Gandhi MC Genovese 2007 Long-term efficacy and safety of Abatacept through 3 years of treatment in rheumatoid arthritis patients in the AIM and ATTAIN Trials Arthritis Rheum 56 Suppl S S300 abstract
26. M Schiff M Keiserman C Codding S Songcharoen A Berman S Nayiager C Saldate T Li R Aranda JC Becker C Lin PL Cornet M Dougados 2008 Efficacy and safety of abatacept or infliximab versus placebo in ATTEST: a phase III, multicenter, randomized, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate Ann Rheum Dis 67 1096 1103
27. HK Genant CG Peterfy R Westhovens JC Becker R Aranda G Vratsanos J Teng JM Kremer 2008 Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long-term extension of the AIM trial Ann Rheum Dis 67 1084 1089
28. JS Smolen C Han M Bala RN Maini JR Kalden D van der Heijde FC Breedveld DE Furst PE Lipsky ATTRACT Study Group 2005 Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study Arthritis Rheum 52 1020 1030
29. L Moreland J Kaine L Espinoza T McCann R Aranda JC Becker J Kremer C Bingham 2005 Safety of abatacept in rheumatoid arthritis patients in five double-blind, placebo controlled trials Arthritis Rheum 52 Suppl S S350 abstract
30. J Reynolds K Shojania CA Marra 2007 Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis Pharmacotherapy 27 1693 1701
31. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann Rheum Dis [Epub ahead of print], 2008
32. CL Bigbee DG Gonchoroff G Vratsanos SG Nadler HG Haggerty JL Flynn 2007 Abatacept treatment does not exacerbate chronic Mycobacterium tuberculosis infection in mice Arthritis Rheum 56 2557 2565
33. L Carmona JJ Gómez-Reino V Rodríguez-Valverde D Montero E Pascual-Gómez EM Mola L Carreño M Figueroa BIOBADASER Group 2005 Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 1766 1772
34. TA Simon Al SMitten M Meng S Suissa J Askling J Franklin M Hochberg D Lacaille 2007 Observed and expected malignancies in the rheumatoid arteritis abatacept clinical development program: an updated epidemiological assessment Arthritis Rheum 56 Suppl S S345 abstract
35. http://www.emea.europa.eu/humandocs/Humans/EPAR/orencia/orencia.htm
36. DJ Todd KH Costenbader ME Weinblatt 2007 Abatacept in the treatment of rheumatoid arthritis Int J Clin Pract 61 494 500
37. M Schiff C Pritchard X Zhou K Bahrt MC Genovese 2007 The efficacy of Abatacept in patients with active Rheumatoid arthritis and an inadequate Response to anti-TNF therapy: the ARRIVE trial Arthritis Rheum 56 Suppl S S391 abstract
38. J Sibilia R Westhovens 2007 Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis Clin Exp Rheumatol 25 5 Suppl 46 S46 S56
39. L Tay F Leon G Vratsanos R Raymond M Corbo 2007 Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects Arthritis Res Ther 9 R38